Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZSTARYS vs DEXTROSTAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older
FDA-approved for attention deficit hyperactivity disorder (ADHD) and narcolepsy. Off-label uses include treatment-resistant depression, obesity, and cognitive enhancement in certain conditions.
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
AZSTARYS is a prodrug that is converted to dexmethylphenidate primarily through enzymatic hydrolysis by carboxylesterase 1 (CES1). The active metabolite dexmethylphenidate is further metabolized primarily via deesterification to ritalinic acid, with minor hydroxylation pathways.
Primarily metabolized by hepatic CYP2D6 enzymes to inactive metabolites; also undergoes deamination and oxidation.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Serdexmethylphenidate: 94% (bound to albumin); dexmethylphenidate: 15-20%.
15-40% bound to plasma proteins, primarily albumin.
Serdexmethylphenidate: 5.6 L/kg; dexmethylphenidate: 2.7 L/kg. High Vd indicates extensive tissue distribution.
Approximately 3-4 L/kg, suggesting extensive tissue distribution.
Oral: 100% for serdexmethylphenidate (prodrug); dexmethylphenidate from the prodrug is 87% bioavailable relative to equivalent dexmethylphenidate dose.
Oral: approximately 60-70% due to first-pass metabolism; extended-release formulations have comparable bioavailability.
e GFR 15-29 m L/min: not recommended; e GFR <15 m L/min: contraindicated. No dose adjustment for e GFR >=30 m L/min.
No specific guideline; use with caution and monitor for adverse effects in severe renal impairment (e GFR <30 m L/min/1.73m²).
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
No specific guideline; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Age 6-12 years: initial 19.6 mg oral once daily; titrate weekly by 19.6 mg; max 78.4 mg. Age 13-17 years: same as adult dosing.
For ADHD: Children 6 years and older, start with 5 mg once or twice daily, increase by 5 mg weekly as tolerated; maximum 40 mg/day. Weight-based: 0.3-0.6 mg/kg/day.
No specific studies in elderly; initiate at low end of dosing range due to increased sensitivity to sympathomimetics. Monitor cardiovascular status.
Start at lower doses, e.g., 2.5 mg once or twice daily, due to increased sensitivity and risk of side effects; monitor blood pressure and cardiac status.
AZSTARYS has a high potential for abuse and misuse, which can lead to dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
High potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: Monitor closely for tachycardia and hypertension.,Psychiatric adverse events: May precipitate psychotic or manic symptoms in patients with no prior history, or exacerbate symptoms in those with pre-existing psychiatric disorders.,Priapism: Prolonged and painful erections may occur, requiring immediate medical attention.,Peripheral vasculopathy: Including Raynaud's phenomenon, monitor for digital changes.,Long-term suppression of growth: Monitor growth in pediatric patients during treatment.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Blood pressure and heart rate increase; monitor for hypertension and tachycardia.,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression.,Seizures: may lower seizure threshold.,Peripheral vasculopathy including Raynaud's phenomenon.,Serotonin syndrome risk if used with serotonergic drugs.,Growth suppression in children; monitor growth during long-term use.
Hypersensitivity to methylphenidate products or any component of AZSTARYS,Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Tics or family history of Tourette's syndrome,Severe anxiety, tension, or agitation
Hypersensitivity to amphetamines or any component of the formulation.,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to hypertensive crisis.,Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse.
High-fat meals delay time to peak concentration (Tmax) by approximately 2 hours but do not affect overall exposure (AUC). Avoid alcohol as it may alter drug release characteristics. No specific food restrictions; can be taken with or without food.
Avoid acidic foods and juices (e.g., orange juice, grapefruit juice) within 1 hour of administration as they can reduce absorption. High-fat meals may delay absorption. Avoid alcohol and caffeine as they can exacerbate side effects.
Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) due to chronic exposure.
First trimester: Limited data, but amphetamine use is associated with increased risk of premature delivery and low birth weight. Second and third trimesters: Risk of fetal growth restriction, increased neonatal heart rate, and neonatal withdrawal syndrome. Avoid use during pregnancy unless potential benefit justifies risk.
Excreted in human milk; M/P ratio not established. Limited data suggest potential for adverse effects in nursing infants (e.g., irritability, poor feeding). Decision to breastfeed should weigh risks and benefits; consider alternative feeding if drug is essential.
Amphetamines are excreted in human milk. M/P ratio not established. Breastfeeding not recommended due to potential adverse effects in infants including irritability, poor feeding, and growth suppression.
No established dose adjustments in pregnancy; however, increased clearance may reduce efficacy. Titrate to lowest effective dose. Consider alternative therapies if possible due to unknown risks.
Pregnancy may increase clearance of amphetamines; dose adjustments may be necessary. Use the lowest effective dose. Clinical monitoring recommended.
AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is a prodrug combination with immediate-release and delayed-release components. Onset of action occurs within 1 hour, and duration is approximately 13 hours. It can be taken with or without food, but high-fat meals delay peak concentration. Avoid use in patients with pre-existing cardiovascular disease, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Monitor for growth suppression in children, weight loss, and insomnia. Avoid concomitant use with MAOIs or within 14 days of discontinuation. May exacerbate tics or Tourette syndrome. Use with caution in patients with seizure disorder or those taking CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) due to increased dexmethylphenidate exposure.
Dextrostat (dextroamphetamine) is a central nervous system stimulant used for ADHD and narcolepsy. Monitor for hypertension, tachycardia, and psychiatric adverse effects. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or severe anxiety. Taper to discontinue to avoid withdrawal. Use with caution in patients with a history of substance abuse. May reduce seizure threshold.
Take exactly as prescribed; do not crush or chew capsules.,Avoid alcohol while taking this medication.,Report any chest pain, shortness of breath, or palpitations immediately.,May cause dizziness or blurred vision; avoid driving until effects are known.,Use with caution in patients with history of drug dependence or abuse.,Keep out of reach of children; do not share medication.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Avoid taking late in the day to prevent insomnia.,Report any chest pain, shortness of breath, or fainting immediately.,Do not crush or chew extended-release capsules.,Avoid alcohol and over-the-counter cold remedies containing decongestants.,Store in a secure place; misuse can cause serious health problems.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZSTARYS vs DEXTROSTAT, answered by our medical review team.
AZSTARYS is a CNS Stimulant that works by AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.. DEXTROSTAT is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZSTARYS and DEXTROSTAT depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZSTARYS is: Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.. The standard adult dose of DEXTROSTAT is: 5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZSTARYS and DEXTROSTAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZSTARYS is classified as Category C. Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, . DEXTROSTAT is classified as Category C. First trimester: Limited data, but amphetamine use is associated with increased risk of premature delivery and low birth weight. Second and third trimesters: Risk of fetal growth r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.